Drug management of obesity--efficacy versus safety.
Astrup
Arne
A
D019440:Anti-Obesity Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001552:Benzazepines / Q000009:adverse effects / Q000627:therapeutic use*; D000075202:Contraindications; D003503:Cyclobutanes; D017277:Drug Approval / Q000331:legislation & jurisprudence; D005277:Fenfluramine / Q000009:adverse effects; D006801:Humans; D009765:Obesity / Q000188:drug therapy*; D050177:Overweight / Q000188:drug therapy; D058826:Serotonin 5-HT2 Receptor Agonists; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D015431:Weight Loss / Q000187:drug effects
D019440:Anti-Obesity Agents; D001552:Benzazepines; D003503:Cyclobutanes; D058826:Serotonin 5-HT2 Receptor Agonists; D017366:Serotonin Receptor Agonists; D005277:Fenfluramine; C506658:lorcaserin; C058254:sibutramine